Growth Differentiation Factor-11
AssigneeThe Johns Hopkins University School of Medicine
InventorsSe-Jin Lee, Alexandra C. McPherron
Life of this patent
Estimating the term…
Abstract
A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-11 (GDF-11) chromosomally integrated into the germ cells of the animal is provided. Also provided are methods for making such animals, and methods of treating animals, including humans, with antibodies or antisense directed to GDF-11. The animals so treated are characterized by increased muscle tissue and bone tissue.
Claims24
1-7. (canceled)
A method of treating a chronic or acute renal disease in a subject having such a disease, comprising administering to the subject a reagent that affects GDF-11 activity or expression.
13-38. (canceled)
A method of inhibiting the growth regulating actions of GDF-11, comprising contacting a GDF-11 agent with fetal or adult muscle cells or progenitor cells.
A method for treating a muscle or adipose tissue disorder in a subject, comprising administering a therapeutically effective amount of a GDF-11 agent to the subject, thereby inhibiting abnormal growth of muscle or adipose tissue.
A method of inhibiting the growth regulating actions of GDF-11 in a subject, comprising administering to the subject, a GDF-11 agent that inhibits the action of GDF-11 in the subject.
The method of 51, wherein the GDF-11 agent is a GDF-11 antisense polynucleotide, a polynucleotide encoding a dominant negative GDF-11 polypeptide, a GDF-11 antibody, or a polynucleotide encoding a truncated GDF-11 polypeptide.
53-54. (canceled)
An isolated polynucleotide encoding a truncated GDF-11 polypeptide, wherein the truncation is a loss of the C-terminal active fragment of GDF-11.
Dependencies are inferred from the claim text.